AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Authors
Keywords
-
Journal
Nature Communications
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-04-18
DOI
10.1038/s41467-019-09734-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours
- (2017) Jordi Rodon et al. EUROPEAN JOURNAL OF CANCER
- Successful Treatment with Gefitinib in Advanced Non–Small Cell Lung Cancer after Acquired Resistance to Osimertinib
- (2017) Nuria Chic et al. Journal of Thoracic Oncology
- The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
- (2017) Céline Clémenson et al. MOLECULAR CANCER THERAPEUTICS
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
- (2017) Kirstine Jacobsen et al. Nature Communications
- IK-guided PP2A suppresses Aurora B activity in the interphase of tumor cells
- (2016) Sunyi Lee et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis
- (2016) Wilhem Leconet et al. CLINICAL CANCER RESEARCH
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- (2016) S. Ortiz-Cuaran et al. CLINICAL CANCER RESEARCH
- Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation
- (2016) Le-Xun Wang et al. Scientific Reports
- Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells
- (2015) Stine Hole et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
- (2015) Samuel H. Myers et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition
- (2015) Heiner Koch et al. JOURNAL OF PROTEOME RESEARCH
- Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
- (2015) Chee-Seng Tan et al. LANCET ONCOLOGY
- Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition
- (2015) Mahito Sadaie et al. MOLECULAR BIOLOGY OF THE CELL
- The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression
- (2015) M. S. Phadke et al. MOLECULAR CANCER THERAPEUTICS
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma
- (2015) Dominik Bogen et al. Oncotarget
- Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
- (2015) Alexander Hoellein et al. Oncotarget
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy
- (2014) Ali Zekri et al. TUMOR BIOLOGY
- Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer
- (2013) Masafumi Takeshita et al. LUNG CANCER
- Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
- (2013) Hideki Terai et al. MOLECULAR CANCER RESEARCH
- S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
- (2013) M. F. Burbridge et al. MOLECULAR CANCER THERAPEUTICS
- Identification of an Aurora Kinase Inhibitor Specific for the Aurora B Isoform
- (2012) H. Xie et al. CANCER RESEARCH
- Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence
- (2012) Yan Liu et al. EMBO Molecular Medicine
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
- (2012) R M A Linger et al. ONCOGENE
- Down-regulation of Aurora B kinase induces cellular senescence in human fibroblasts and endothelial cells through a p53-dependent pathway
- (2011) Hee-Jin Kim et al. FEBS LETTERS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Visualizing histone modifications in living cells: spatiotemporal dynamics of H3 phosphorylation during interphase
- (2009) Yoko Hayashi-Takanaka et al. JOURNAL OF CELL BIOLOGY
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started